C4 Therapeutics, Inc.

NasdaqGS:CCCC Stock Report

Market Cap: US$418.3m

C4 Therapeutics Past Earnings Performance

Past criteria checks 0/6

C4 Therapeutics's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 34.1% annually. Revenues have been declining at an average rate of 3.8% per year.

Key information

-2.68%

Earnings growth rate

12.16%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-3.80%
Return on equity-41.02%
Net Margin-289.44%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Seeking Alpha • Sep 05

C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts

Summary C4 Therapeutics is rated Hold, with valuation hinging on the Phase 2 success of its lead asset, cemsidomide. CCCC holds $300.4 million in cash, providing runway through late 2028 and supporting ongoing clinical and partnered programs. The calculated fair value per share is $3.32, below the current $3.71 price, reflecting significant risk if cemsidomide fails. Phase 2 MOMENTUM trial data in late 2027 is the critical catalyst; success could raise fair value to $5.32 per share. Read the full article on Seeking Alpha
Analysis Article • Aug 14

Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) just released its latest quarterly results and things are looking bullish...
Analysis Article • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
Analysis Article • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
Analysis Article • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
Analysis Article • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
Analysis Article • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
Analysis Article • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
Analysis Article • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
Analysis Article • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
Analysis Article • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
Analysis Article • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
Analysis Article • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
Analysis Article • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
Analysis Article • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

Revenue & Expenses Breakdown

How C4 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:CCCC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2635-1013695
31 Mar 2635-1043695
31 Dec 2536-1053695
30 Sep 2530-119370
30 Jun 2534-1124098
31 Mar 2540-1034198
31 Dec 2436-1054298
30 Sep 2434-105420
30 Jun 2429-108410
31 Mar 2420-126410
31 Dec 2321-132420
30 Sep 2320-135420
30 Jun 2316-140410
31 Mar 2327-131410
31 Dec 2231-128430
30 Sep 2248-107410
30 Jun 2250-99400
31 Mar 2246-95390
31 Dec 2146-84330
30 Sep 2134-80310
30 Jun 2134-82260
31 Mar 2134-73200
31 Dec 2033-66150
30 Sep 2033-67110
30 Jun 2030-52110
31 Mar 2024-47100
31 Dec 1921-4390
31 Dec 1819-2470

Quality Earnings: CCCC is currently unprofitable.

Growing Profit Margin: CCCC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CCCC is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare CCCC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CCCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64.6%).

Return on Equity

High ROE: CCCC has a negative Return on Equity (-41.02%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 15:31
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

C4 Therapeutics, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets